Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy

Morinaga, Daisuke; Sakakibara-Konishi, Jun; Kawai, Yasutaka et al.

Respiratory Investigation, 2025, 63(3), 423-430

Permalink : https://hdl.handle.net/2115/97519

このアイテムのアクセス数:51件（2026-10-17 00:41 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
HUSCAP_SCLC_2nd_line_Manuscript_for_Submission_post revision ver1.0 clean version pdf 698 KB 60
Supplemental Figure1_PPT pptx 59.2 KB 8
Supplementary_material docx 28.4 KB 13

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/97519
タイトル
Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy
著者
Morinaga, Daisuke ; Sakakibara-Konishi, Jun ; Kawai, Yasutaka ; Morinaga, Yumi ; Mizobuchi, Shohei ; Okamoto, Yoshihiro ; Yamanaka, Yasunari ; Takahashi, Kei ; Kikuchi, Hajime ; Sukoh, Noriaki ; Takashina, Taichi ; Kitai, Hidenori ; Konno, Satoshi
著者名
Morinaga, Daisuke
e-Rad_Researcher
50374278
著者名
Sakakibara-Konishi, Jun
著者名
Kawai, Yasutaka
著者名
Morinaga, Yumi
著者名
Mizobuchi, Shohei
著者名
Okamoto, Yoshihiro
著者名
Yamanaka, Yasunari
著者名
Takahashi, Kei
著者名
Kikuchi, Hajime
著者名
Sukoh, Noriaki
著者名
Takashina, Taichi
e-Rad_Researcher
30975412
著者名
Kitai, Hidenori
e-Rad_Researcher
20399835
著者名
Konno, Satoshi
言語
英語
キーワード
Extensive-stage small cell lung cancer
Immune checkpoint inhibitor
Combination therapy
Second-line therapy
発行日
2025-03-22
出版者
Elsevier
収録物名
Respiratory Investigation
巻(号)
63(3)
ページ
423-430
抄録
Background: Immune checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy (ICI-chemo) have become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, the effect of ICIchemo on the efficacy of subsequent chemotherapy remains unknown. This study aimed to investigate the efficacy of second and subsequent treatments of SCLC with and without ICI combination therapy. Methods: We performed an analysis of patients with ES-SCLC between January 2015 and June 2023. The ICIchemo groups were defined as patients who received ICI-chemo as first-line therapy between September 2019 and June 2023, after ICI-chemo was reimbursed in Japan. The non-ICI-chemo groups were defined as patients who received platinum-doublet therapy between January 2015 and August 2019 and were considered eligible for ICI-chemo. Results: In total, 224 patients were included (91 and 133 patients who received ICI-chemo and non-ICI-chemo, respectively). There were no significant differences in patient characteristics between the groups. There was no significant difference in progression-free survival (PFS) and overall survival (OS) for first-line treatment between the two groups. The median PFS and OS periods for second-line treatment were 3.9 and 3.9 months and 10.3 and 10.7 months in the ICI-chemo and non-ICI-chemo groups, respectively, without significant difference. Most patients in both groups received amrubicin as the second-line treatment. Moreover, the PFS and OS periods for third-line treatment were not significantly different between the ICI-chemo and non-ICI-chemo groups. Conclusions: In ES-SCLC, there is no significant additive effect on PFS and OS of second- and subsequent line treatments following ICI-chemo at first-line treatment.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報
©2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN
2212-5345
EISSN
2212-5353
関連情報
PMID
40120158
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1016/j.resinv.2025.03.013